Signum Biosciences aims to develop novel G-protein coupled receptor (GPCR) modulating therapeutics to treat common skin disorders.
Signum intends to use the first SBIR grant to develop anti-inflammatory agents to reduce chronic redness (erythema) associated with eczema, atopic dermatitis, and rosacea.
The second SBIR grant will fund Signum’s identification and development of multi-functional, safe, topical anti-acne therapeutics.
Signum CEO Braham Shroot said that their objective continues to be development of their technology with the goal of improving quality of life for the large number of patients suffering from skin disease.
Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from its Signal Transduction Modulation (STM) platform to modulate signal transduction imbalances.